BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 17003814)

  • 1. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P; Persson PB; Hansell P; Lagerqvist B
    Kidney Int; 2006 Nov; 70(10):1811-7. PubMed ID: 17003814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
    Le Feuvre C; Batisse A; Collet JP; Batisse JP; Choussat R; Beygui F; Helft G; Montalescot G; Metzger JP
    Catheter Cardiovasc Interv; 2006 Jun; 67(6):852-8. PubMed ID: 16649230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
    Song T; Song M; Ge Z; Li Y; Shi P; Sun M
    J Interv Cardiol; 2017 Jun; 30(3):281-285. PubMed ID: 28421628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study.
    Bellemain-Appaix A; Beygui F; Lesty C; Gupta S; Silvain J; Le Feuvre C; Cayla G; Allali Y; Montalescot G; Collet JP
    Catheter Cardiovasc Interv; 2012 Apr; 79(5):823-33. PubMed ID: 21618678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the risk of total cardiovascular events of isosmolar iodixanol compared with low-osmolar contrast media.
    Zhang BC; Wu Q; Wang C; Li DY; Wang ZR
    J Cardiol; 2014 Apr; 63(4):260-8. PubMed ID: 24397991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease.
    Tadros GM; Malik JA; Manske CL; Kasiske BL; Dickinson SE; Herzog CA; Wilson RF; Das G; Panetta CJ
    J Invasive Cardiol; 2005 Apr; 17(4):211-5. PubMed ID: 15831975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME; Esplugas E; Piessens J; Rasch W
    Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
    From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
    Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
    N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal effects of cardiac angiography with different low-osmolar contrast media.
    Donadio C; Lucchesi A; Ardini M; Tramonti G; Chella P; Magagnini E; Bianchi C
    Ren Fail; 2001; 23(3-4):385-96. PubMed ID: 11499554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration.
    Lasser EC; Lyon SG; Berry CC
    Radiology; 1997 Jun; 203(3):605-10. PubMed ID: 9169676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Bolognese L; Falsini G; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    J Cardiovasc Med (Hagerstown); 2010 Mar; 11(3):199-206. PubMed ID: 19829124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.